Literature DB >> 2834995

Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans.

C E Hughes1, R L Bennett, I C Tuna, W H Beggs.   

Abstract

We have compared the activities of fluconazole and ketoconazole against ketoconazole-susceptible and -resistant strains of Candida albicans in a neutropenic-site rabbit model. Oral treatment with fluconazole resulted in much higher serum and extravascular concentrations of this antifungal agent than did comparable doses of ketoconazole. Fluconazole had no additional in vivo activity against the ketoconazole-susceptible strains; no fungicidal activity was observed with peak drug levels as high as approximately 75 micrograms/ml in the infection sites. Significant fungistatic activity against the ketoconazole-resistant strains was observed with fluconazole treatment (80 mg/kg), but not with less fluconazole (20 mg/kg) or with ketoconazole (approximately 67 mg/kg). In vitro susceptibility tests separated the ketoconazole-susceptible strains from the ketoconazole-resistant strains, but the results were variable when the resistant strains were tested with fluconazole.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2834995      PMCID: PMC172136          DOI: 10.1128/AAC.32.2.209

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits.

Authors:  J R Perfect; D T Durack
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

2.  Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.

Authors:  M J Humphrey; S Jevons; M H Tarbit
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

3.  Ketoconazole and the liver.

Authors:  C R Horseburgh; C H Kirkpatrick; C B Teutsch
Journal:  Lancet       Date:  1982-04-10       Impact factor: 79.321

4.  Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo.

Authors:  T E Rogers; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

5.  Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice.

Authors:  P F Troke; R J Andrews; K W Brammer; M S Marriott; K Richardson
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

6.  Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.

Authors:  J R Perfect; D V Savani; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

7.  Ketoconazole and flucytosine alone and in combination against Candida spp. in a neutropenic site in rabbits.

Authors:  C E Hughes; L R Peterson; W H Beggs; D N Gerding
Journal:  J Antimicrob Chemother       Date:  1986-07       Impact factor: 5.790

8.  Growth phase in relation to ketoconazole and miconazole susceptibilities of Candida albicans.

Authors:  W H Beggs
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

9.  Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size.

Authors:  J N Galgiani; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

10.  Simplified bioassay method for measurement of flucytosine or ketoconazole.

Authors:  C A Bodet; J H Jorgensen; D J Drutz
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

View more
  18 in total

1.  In vitro studies of activities of some antifungal agents against Candida albicans ATCC 10231 by the turbidimetric method.

Authors:  M T Blanco; C Pérez-Giraldo; J Blanco; F J Morán; C Hurtado; A C Gómez-García
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

2.  In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum.

Authors:  G S Kobayashi; S J Travis; M G Rinaldi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

Review 3.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

Review 4.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

Review 5.  Antifungal susceptibility testing.

Authors:  J H Rex; M A Pfaller; M G Rinaldi; A Polak; J N Galgiani
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

6.  Fluconazole penetration into the pancreas.

Authors:  S Shrikhande; H Friess; C Issenegger; M E Martignoni; H Yong; B Gloor; R Yeates; J Kleeff; M W Büchler
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

7.  Fluconazole (UK-49,858) treatment of candidiasis in normal and diabetic rats.

Authors:  M A Fisher; P G Lee; W F Tarry
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

8.  Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography.

Authors:  A J Fischman; N M Alpert; E Livni; S Ray; I Sinclair; R J Callahan; J A Correia; D Webb; H W Strauss; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

9.  In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus.

Authors:  F Barchiesi; A L Colombo; D A McGough; A W Fothergill; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.

Authors:  T Peng; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.